The BRAFV600E mutation analysis and risk stratification in papillary thyroid carcinoma

• Published in: Archives of Endocrinology and Metabolism 2020-08, Vol.64 (6), p.751-757
• Main Authors: Scheffel, Rafael Selbach, Cristo, Ana Patrícia de, Romitti, Mirian, Vargas, Carla Vaz Ferreira, Ceolin, Lucieli, Zanella, André B., Dora, Jose Miguel, Maia, Ana Luiza
• Format: Article
• Language: English
• Subjects: BRAF mutation; Original; Papillary thyroid carcinoma; persistent disease; risk classification
• ISSN: 2359-3997; 2359-4292
• DOI: 10.20945/2359-3997000000285

ABSTRACT Objective: Although the prognostic role of BRAFV600E mutation in papillary thyroid carcinoma (PTC) is controversial, the American Thyroid Association (ATA) includes the mutational status in their risk stratification system. To evaluate the impact of the BRAFV600E mutation status on PTC risk stratification. Subjects and methods: PTC patients attending a university-based hospital who had the analysis of the BRAFV600E mutation were included. Persistent disease was defined as the presence of biochemical or structural disease. The performance of the ATA risk stratification system on predicting persistent disease with or without the BRAFV600E mutation status information was evaluated. Results: Of the 134 patients evaluated, 44 (32.8%) carried BRAFV600E mutation. The median tumor size was 1.7 cm (P25-75 1.0-3.0), 64 (47.8%) patients had lymph node, and 11 (8.2%) distant metastases. According to the ATA risk stratification system, patients were classified as low, intermediate, and high risk in 55 (41%), 59 (44%), and 20 (14%) patients, respectively. The data on BRAFV600E mutation reclassified 12 (8.9%) patients from low to intermediate risk. After a median follow-up of 8.5 years, the prevalence of persistent disease was similar in patients with and without BRAFV600E mutation (P = 0.42). Multivariate analysis failed to demonstrate an association between the BRAFV600E mutation and persistent disease status (RR 0.96; 95%CI 0.47-1.94). Notably, none of the patients reclassified from low to intermediate risk showed persistent disease on follow-up. Conclusion: Inclusion of BRAFV600E mutational status has a limited impact on risk stratification and does not add to the prediction of outcomes in PTC patients.